Member Info for Buildworker

They do like to repeat themselves, most of this we already knew. Preparing to be underwhelmed by market response, but will be delighted if, as on many occasions, I’m proved wrong and SP flies.

Good luck with getting that reply!

Hi Kevin, I agree with you point, desperate people will pay whatever necessary. My pov, I’m 62 and need a little boost now and then, but at £6 a pop I’ll use something else. Scotch bonnet, garlic and ginger works for me!

Also, with revenue rolling in, I’d like to see a big increase in their R&D spend, with recruitment of top class research scientists etc, as at the moment Futura are very much a one trick pony. I think I read somewhere that they have just 12 employees, so most of them will be directors and admin, so who is spearheading the development of next generation products?

For me, this about the trajectory that the first three months have indicated. I suspect there was an initial surge in sales, when the product first hit the market, then a dip as people with overly high expectations, left negative reviews, which has dented confidence in the product.

I’ve said this before, but will repeat myself, I think the product is overpriced and poorly presented. But, as others have said, it will find its niche and it’s not yet widely available outside of UK and some EU regions.

So, the upshot is that it’s the guidance given for the next 6 months to full year results, which will be important. It will certainly determine whether I decide to continue to hold, or take my current profits. At least this is one stock in my portfolio that has the right colour next to it!

Www.eroxongel.com

Looks like Eroxon but more than twice the price, is it a scam? Certainly doesn’t help the brand reputation.

I guess we shouldn’t be surprised that the latest RNS did little to boost SP, when Kingdom of SA has a population of 36 million c.f. USA 330 million and FDA approval plus Haleon partnership also did little to improve SP. We’re a few weeks away from release of interim results, which should be outstanding if fire side chat is anything to go by. I expect to see the SP tick up as we approach results day and really hoping for a major surge once real profits can be seen. My old Volvo’s got 180, 000 on the clock and needs updating!

There seems to be a distinct paucity of marketing of Eroxon to the wider European markets.

Cooper Consumer Healthcare are doing zero marketing as far as I can tell. Their website hasn’t published a press release for 3 years, suggesting there is no marketing department. You can find Eroxon under their brands, but that simply links to Futura’s Eroxon site. When you enter France or Germany in the geographical search, there are no results.

Now FUM have some revenue coming in, I think it’s time they and their partners upped their game and get the message out to the big Euro economies. Just my opinion of course, but I’m becoming increasingly frustrated at the lack of upward momentum with this stock.

Ditto, wish I’d had a bit more free cash to invest as this was a slam dunk.

Disappointing fall back of SP.

Interesting that press release refers only to MED3000 and not Eroxon. Hopefully lessons have been learnt from European launch and product will be better branded, packaged and more realistically priced to attract larger market of recreational users.

Hello Banzai, I have no empirical data, just observation of purchases via Boots web site and inference from the number of negative reviews. For sure, there was an initial surge in sales, but that appears to have tailed off. Expectations have been set too high, in part driven by the premium price. I believe a better value for money strategy and simple delivery system would help address the negative feedback. I want this to succeed as much as anyone on here!

Last thing I want to do is deramp, as I have a lot to lose. I’m putting myself in the position of a customer and what would make me want to always have this product in my bedside cabinet.

Efficacy, price and ease of use. For what it’s worth, just prior to FDA approval I put another £10k into FUM, a the same time as £10k into THG. FUM currently showing 24% gain, THG 34% gain..

Thanks for your input Jet. Why do you feel you couldn’t use a dispenser?

Re: Amazon sales, my concern is how many of these will become repeat customers. I suspect the majority will try it once only, but conclude not enough bang fo their buck and too tedious to use. At £6+ a dose, your focus is more likely to be to ensure you squeeze every last drop out off the tiny tube to get your money’s worth, expecting something miraculous to happen. I suggest it should be be in a simple to use and easily accessible pump action dispenser, which allows you to keep the spontaneity of the moment, and at a price which encourages you to persevere.

I’ve been keeping tabs on their website and for the first few weeks post launch you could see 100+ sold in the last 24hrs. Not sure if that is a rolling 24 hour period or a daily 24 hours. Also product flying off shelves in store. Look now and there are barely 12 added to basket in the last 24 hours and loads of stock in store.. In other words a 90% fall. Probably to be expected to some extent, but I still believe the price point is too high and the packaging is not conducive to easy use. These can be addressed by FUM and Coopers, to generate much greater ongoing sales, albeit at slightly reduced margins.

I would further comment that I hope FUM and partners are taking note of the feedback to date and quickly realign their strategy before US launch, as it’s clear from Boots website that sales have fallen off a cliff. Pitched at the right price and in an easy to apply dispenser can still allow Eroxon to fly, as both an ED treatment and a recreational boost.

IMO FUM have got this wrong in a number of ways. Firstly, pricing strategy is way off. They’ve tried to align it with the likes of Viagra and Cialis, which when introduced were novel treatments. However, the price point for their generic equivalents is now as low as £1 per dose, so Eroxon is way out of step. Furthermore, when you look at the ingredients, you don’t need degree in chemistry to understand these are common base ingredients used in a multitude of skin care and hygiene products, so it feels overpriced. The problem with the high price tag is that it raises expectations to an unreasonably high level and amplifies the dissatisfaction feeling when you don’t get the response you hoped for. Hence so many negative reviews.

It’s stated that the efficacy improves with further use, but the problem with this is that the initial response and dose price has already set a seed of failure in the minds of users - just another ‘miracle cure’ con. I think Eroxon, as a novel treatment, can carry a small premium, but £2 per dose would achieve greater acceptance and willingness to persevere.

Secondly, packaging. In order to justify the price tag and presumably give the product some kind of upmarket medical feel, it’s presented in tiny individual dose tubes. This makes it a cumbersome and fiddly process to apply the product in you moment of passion and all spontaneity is lost. IMO, it should be presented in a high quality, premium feel, multi dose pump action dispenser. Something that can be kept bedside and ready to go and encourage users to slap it on. As there’s no active drug, there’s no issue with overdosing.

Like many others here, I thought this stock would take off with FDA approval, so really disappointed with today’s close. We need a trading update from FUM to reassure us that this is worth sticking with.

Imminent announcement of US distributor should see a further surge in SP.

Product is now available across Europe via New Pharma and others. Just ordered some from them as I’m staying in France. Only 7 reviews so far, but mostly positive. Will give my honest opinion once tested. Boots must be selling thousands of packs per week, so could be in the tens of thousands across Europe. A trading update from FUM would be welcome.